Invesco Ltd. Boosts Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Invesco Ltd. raised its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 50.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 174,998 shares of the medical instruments supplier's stock after buying an additional 58,720 shares during the period. Invesco Ltd. owned 0.78% of LeMaitre Vascular worth $16,124,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of LMAT. New York State Teachers Retirement System grew its position in LeMaitre Vascular by 1.2% during the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock valued at $755,000 after buying an additional 100 shares during the period. Flputnam Investment Management Co. boosted its stake in LeMaitre Vascular by 3.6% in the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock valued at $269,000 after acquiring an additional 102 shares during the last quarter. Norden Group LLC grew its position in shares of LeMaitre Vascular by 4.5% during the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after acquiring an additional 103 shares during the period. Blue Barn Wealth LLC raised its holdings in shares of LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock worth $229,000 after purchasing an additional 104 shares during the period. Finally, Shaker Investments LLC OH increased its position in LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock worth $1,285,000 after buying an additional 112 shares during the last quarter. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Performance

NASDAQ LMAT traded down $0.99 on Friday, hitting $90.78. The stock had a trading volume of 24,798 shares, compared to its average volume of 160,921. The firm has a 50-day moving average of $87.08 and a 200-day moving average of $93.41. LeMaitre Vascular, Inc. has a 52-week low of $62.50 and a 52-week high of $109.58. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of 49.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. As a group, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.88%. LeMaitre Vascular's payout ratio is presently 41.24%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, LeMaitre Vascular has a consensus rating of "Moderate Buy" and an average target price of $95.25.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.